Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures

Abstract

Combining stratification by PHS and selection of a sensitive combined outcome measure in a cohort of patients with MCI can allow trial design that is more efficient, potentially less burdensome on participants, and more cost effective.